Form 4: Alnylam Pharmaceuticals Executive Pushkal Garg Reports Stock and Option Awards

Pushkal Garg, CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, reports the acquisition of restricted stock units and stock options, along with adjustments to existing holdings.

Summary

• Pushkal Garg, a key executive at Alnylam Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2024, Garg acquired 4,751 restricted stock units (RSUs) under the company's stock incentive plan, which will vest over three years.
• Garg also received a stock option to purchase 9,279 shares of common stock at an exercise price of $152.61, vesting over four years.
• The report indicates Garg holds 13,417 shares of common stock directly, 431 shares indirectly through a managed account, and 250 shares indirectly through a trust.
• The filing also covers adjustments to previously reported RSU awards.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The equity grants indicate confidence in the executive and the company's future, but it's a routine filing.

Positives

• The grant of RSUs and stock options aligns the executive's interests with the company's long-term performance.
• The vesting schedules encourage continued service and contribution to Alnylam's success.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued growth and value creation.

Industry Context

Equity grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. The vesting schedules are typical for such grants.

Comparison to Industry Standards

• Equity compensation packages for executives in biotech companies of Alnylam's size typically include a mix of stock options and restricted stock units.
• Vesting schedules of three to four years are standard in the industry to ensure long-term alignment with company goals.
• Comparable companies like Ionis Pharmaceuticals and Sarepta Therapeutics also utilize similar equity-based compensation strategies.

Stakeholder Impact

• The equity grants align management's interests with those of shareholders, potentially driving long-term value creation.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates